SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.

Andrea Necchi,Daniele Raggi,Marco Bandini,Andrea Gallina,Umberto Capitanio,Giorgio Gandaglia,Vito Cucchiara,Nicola Fossati,Francesco De Cobelli,Andrea Salonia,Gromek Smolen,Sohail Balasubramanian,Ewan A. Gibb,Jeffrey S. Ross,Russell Madison,Alberto Briganti,Stefano Cascinu,Francesco Montorsi

SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.

2021

Andrea Necchi
Daniele Raggi
Marco Bandini
Andrea Gallina
Umberto Capitanio
Giorgio Gandaglia
Vito Cucchiara
Nicola Fossati
Francesco De Cobelli
Andrea Salonia
Gromek Smolen
Sohail Balasubramanian
Ewan A. Gibb
Jeffrey S. Ross
Russell Madison
Alberto Briganti
Stefano Cascinu
Francesco Montorsi

TPS506Background: MIBC is a systemic disease as >40% of patients (pts) ultimately develop recurrence after radical cystectomy (RC). For pts who cannot receive or refuse cisplatin-based chemotherapy...

Keywords:

Urology
Cisplatin
Systemic disease
Bladder cancer
Pembrolizumab
Sacituzumab govitecan
Chemotherapy
Phases of clinical research
Cystectomy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations